Trials / Completed
CompletedNCT04390477
Study to Evaluate the Effect of a Probiotic in COVID-19
The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Bioithas SL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients with negative PCR after infection with the coronavirus SARS-CoV-2.
Detailed description
In this study, the investigators hypothesize a positive effect of probiotic on the gut microbiome that could led to produce a less severe clinical evolution of the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Probiotic | Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days. |
Timeline
- Start date
- 2020-05-04
- Primary completion
- 2021-03-21
- Completion
- 2021-04-30
- First posted
- 2020-05-15
- Last updated
- 2022-04-29
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04390477. Inclusion in this directory is not an endorsement.